STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 finan ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

Bausch + Lomb (NYSE:BLCO – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens ...

Bausch Health shares rose Thursday morning after the company raised its full year outlook following a better-than-expected third-quarter performance. Shares traded over 11% higher in Toronto at 12.68 ...

In a report released yesterday, Douglas Miehm from RBC Capital assigned a Buy rating to Aurinia Pharmaceuticals (AUPH – Research Report), ...

Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & ...

Bausch & Lomb is one of the largest vision care companies ... surgical, and ophthalmic pharmaceuticals. Vision cares make up about 60% of total sales and is composed of contact lenses, lens ...